Should you build or buy Healthcare Commercial Intelligence?
Healthcare commercial intelligence software gives pharma and medtech commercial teams curated data on healthcare providers, organizations, and affiliations, plus patient-level claims, to target sales, marketing, and market access efforts. Commercial and market access teams buy it to know which providers and accounts matter, without assembling the underlying data themselves.
Buy the data. Public sources do not validate credentials, do not carry affiliations and do not include commercial claims, and every documented in-house platform still licenses the vendor file underneath. Put engineering into identity resolution, CRM joins and scoring, where the savings the Cognizant case reported actually came from.
Build it, buy it, or bridge?
When building makes sense
There is a genuine build case here, but it sits on top of licensed data rather than replacing it. A Tiger Analytics case study describes an unnamed US pharmaceutical company that built an in-house platform on AWS SageMaker to chart oncology patient journeys and profile Healthcare Providers more accurately, running it against claims data and third-party EMR data the company had already licensed, replacing a slower process built on two-month-old data with near-real-time weekly claims. A separate Cognizant case study describes an unnamed pharma client that integrated 20 internal and external data sources into a cloud platform generating daily rep account recommendations, reporting $450,000 in annual savings over the manual process it replaced. PwC built a similar HCP360 capability on Salesforce CDP for an unnamed specialty pharma client. In all three cases the build was identity resolution, scoring, and CRM or data-platform integration, the work that turns licensed data into a usable targeting system, not the underlying reference file or claims asset itself. A lean internal analytics team supporting that kind of build is a real staffing commitment, but a fraction of what assembling the claims and reference data from scratch would cost.
When buying makes sense
Buying the data is not optional in any practical sense, and that is what makes the case here so clear. IQVIA OneKey alone covers 25 million healthcare professionals across 117 countries, a scale no commercial team assembles from public sources like NPPES or Open Payments, which carry no affiliations, no validated credentials, and no claims. CMS also bars identifiable Part D claims from commercial use, closing off the most direct public substitute. Broad real-world-data subscriptions run $0.5 million to $5 million a year, a fraction of what building an equivalent claims asset from scratch would cost, which makes licensing the obvious choice before even counting the years it would take to negotiate the data-sharing agreements a vendor already has in place. License the reference and claims assets, and put engineering effort into the identity resolution, CRM joins, and scoring layer where the actual savings show up.
The desk read
Build-versus-buy analysis for Healthcare Commercial Intelligence is being written. In the meantime, the framework that drives every B4 call is on the B4 Index page.
Frequently asked
Why can't a pharma company just use public data instead of licensing a commercial intelligence platform?
Public sources like NPPES and Open Payments list providers but carry no validated credentials, no affiliation data, and no patient-level claims. CMS also restricts identifiable Part D claims from commercial use, removing the most obvious public substitute for licensed claims data.
What does building actually replace in this category, if anything?
Usually the targeting and scoring layer, not the data. A Tiger Analytics case study describes a pharma company that built an AWS SageMaker platform for oncology provider profiling on data it had already licensed, replacing a slower process built on two-month-old data with near-real-time weekly claims, and a separate Cognizant case study describes a pharma client that integrated 20 data sources into a recommendation platform and reported $450,000 a year in savings over its prior manual process. The claims and reference data underneath still came from a licensed source.
How much healthcare data do commercial intelligence vendors actually license?
IQVIA OneKey alone covers 25 million healthcare professionals across 117 countries with real-time updates, and vendors in this category layer patient-level claims spanning hundreds of millions of lives on top of that reference data. That scale is why building an equivalent claims and reference asset from scratch would take years.
What are the main healthcare commercial intelligence vendors?
Representative vendors include Definitive Healthcare Platform, H1 (formerly Carevoyance/Acuity), IQVIA OneKey, H1. Coverage of your specific therapy areas, claims depth matter more here than any feature comparison. B4 Pro includes the category score and the full vendor list.